drugset / Trial / NCT03661567

Methylprednisolone After Split-course Chemoradiotherapy For Bulky Local Advanced None-small Cell Lung Cancer

NCT03661567

Phase 2 Terminated 52 enrolled Sun Yat-sen University
RandomizedParallel-groupOpen-labelTreatment

Summary

This Phase II randomized controlled study is to determine the efficacy of the preventively use of methylprednisolone after split-course chemoradiotherapy (CCRT) in locally advanced non-small cell lung cancer with bulky tumor.

Timeline

Start
2018-08-09
Primary completion
2021-09-10
Completion
2021-09-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylprednisolone Other / unclassified
Background Docetaxel Small molecule 25 mg/m2
Background Nedaplatin Small molecule 25 mg/m2